The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
The recent inspection covered both cGMP and PAI processes
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
Subscribe To Our Newsletter & Stay Updated
